Revvity, Inc. has announced Signals for Startups, a new programme from its Revvity Signals Software business designed to help emerging biotechnology companies establish scalable informatics capabilities from the earliest stages of their growth. Built specifically for early-stage biotechs, the programme combines access to enterprise-grade Signals software with guided onboarding and best-practice configurations, with the stated aim of accelerating innovation, improving scientific productivity and shortening time-to-value.

Addressing resource constraints in early-stage research

For clinical laboratory scientists and informatics teams working within young biotech organisations, the challenge of establishing robust data infrastructure while operating with limited IT and operational resources is a familiar one. Startup biotechs are often under pressure to move quickly with limited IT, informatics and operational resources while managing increasingly complex discovery data, according to Revvity. Signals for Startups has been positioned to address this challenge through a purpose-built, scalable Signals environment intended to allow teams to focus on scientific work while establishing a digital foundation from the outset. Out-of-the-box configurations for large and small molecules are included, enabling companies to standardise data and enhance collaboration on what the company describes as a proven, scalable informatics infrastructure.

Kevin Willoe, president of Revvity Signals Software, commented: “Signals for Startups addresses a critical need for emerging biotech companies that want to move fast without creating data and workflow challenges that limit their ability to scale. By combining startup-friendly access with guided onboarding and scalable Signals workflows, we are helping early-stage teams build the digital foundation they need to advance discovery, support investor readiness and grow with confidence.”

Structured entry point with a path to scale

Signals for Startups is designed to provide a structured entry point into the wider Revvity Signals portfolio, with bundled licences suited to companies at the seed stage through to subsequent venture investment rounds. The intention, according to Revvity, is to help startups avoid fragmented systems and disconnected data practices that can slow progress, increase rework and create difficulties as research programmes mature. The programme is expected to be available in the United States and across Europe, the Middle East and Africa in late July 2026.

Part of a broader expansion of Signals AI capabilities

The launch follows recent developments across Revvity’s Signals portfolio more broadly. In June 2026, the company introduced Signals AI, a native agentic framework built into the Signals One™ platform, intended to allow scientists to search, understand and act on connected R&D data using natural language within their existing workflows. According to Revvity, this capability is grounded in structured scientific data, domain ontologies and validated scientific algorithms, with the intention of delivering traceable, scientifically relevant responses alongside interactive views of molecules, sequences, experimental results and connected knowledge.

Willoe noted at the time: “For decades, scientific software has organized information into predefined applications, workflows and dashboards. The new features Signals AI introduces provide a new model where researchers can engage directly with organizational knowledge, ask questions in natural language and dynamically transform information. By combining the adaptive reasoning of modern AI with trusted scientific intelligence, Revvity’s Signals AI helps organizations accelerate insight
without compromising scientific rigor.”

More recently, in July 2026, Revvity Signals Software joined Anthropic’s directory for Model Context Protocol (MCP) connectors, extending Signals AI capabilities beyond the Signals One platform so that scientists can access connected R&D knowledge through Claude, including Claude Science, Anthropic’s AI workbench for scientific research. Through the Signals MCP connector, Claude is able to securely access information via Signals’ intelligence layer, supporting researchers as they search, understand and act on complex R&D data using natural language, while the company states that traceability and scientific precision are maintained.

Willoe commented on the integration: “By joining Anthropic’s MCP ecosystem, we’re extending the reach of our Signals AI beyond our Signals One platform and enabling researchers to combine Claude’s reasoning capabilities with the governed data, ontology-driven scientific context and trusted knowledge managed across the entire Revvity Signals offering.”

Taken together, these developments indicate a continued build-out of Revvity’s informatics offering across the customer lifecycle, from early-stage biotechs establishing their first digital foundations through to larger organisations extending AI-assisted analysis across existing Signals deployments.

For more information, visit: https://revvitysignals.com/signals-startups

Digital issue: Please click here for more information